Evidence map›Paper›PMID 30897373›Full record

ArticleThe International journal on drug policy2019

Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study.

Stephanie Parent, Seonaid Nolan, Nadia Fairbairn, Monica Ye, Anthony Wu, Julio Montaner, Rolando Barrios, Lianping Ti, STOP HIV AIDS Study Group

Open access · greenAbstract read
In one paragraph

Article in The International journal on drug policy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Stephanie ParentBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Seonaid NolanBritish Columbia Centre on Substance Use, 400-1045 HOwe Street, Vancouver, BC, V6Z 2A9.
Nadia FairbairnBritish Columbia Centre on Substance Use, 400-1045 HOwe Street, Vancouver, BC, V6Z 2A9.
Monica YeBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Anthony WuBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Julio MontanerBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Rolando BarriosBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Vancouver Coastal Health, 520 West 6(th)Avenue, Vancouver, BC V6Z 4H5, Canada.
Lianping TiBritish Columbia Centre on Substance Use, 400-1045 HOwe Street, Vancouver, BC, V6Z 2A9; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. Electronic address: lianping.ti@bccsu.ubc.ca.
STOP HIV AIDS Study Group
Ministry of Health · CASt. Paul's Hospital · CAAIDS Vancouver · CABritish Columbia Centre on Substance Use · CAVancouver Coastal Health · CABC Centre for Disease Control · CASt. Paul's Hospital · CAUniversity of British Columbia · CA

Funding

Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDUDP1DA026182 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MONTANER, JULIO SERGIO GONZALEZ · 2008 to 2013
$3.9M
Mentoring the next generation of addiction clinician scientists while responding to the opioid epidemicR25DA037756 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI FAIRBAIRN, NADIA · 2014 to 2023
$3.6M
Seek and Treat for Optimal Prevention of HIV & AIDS (STOP HIV/AIDS) in BCR01DA036307 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MONTANER, JULIO SERGIO GONZALEZ · 2013 to 2017
$3.0M
NIDA NIH HHS DP1 DA026182NIDA NIH HHS R01 DA036307NIDA NIH HHS R25 DA037756
6 · The paper itself

Abstract

backgroundCo-prescribing benzodiazepines and opioids is relatively contraindicated due to the possible overdose risk. However, people living with HIV (PLWH) may have concurrent psychiatric and/or chronic pain diagnoses that may lead to the use of opioids and/or benzodiazepines for symptomatic treatment. Consequently, some PLWH may be at-risk for the health harms associated with the co-prescribing of these medications. Given this, the objectives of this study were to first examine the prevalence of opioids and benzodiazepines co-prescribing, and second, to characterize patient factors associated with the co-prescribing of opioids and benzodiazepines among PLWH in British Columbia (BC), Canada.

methodsUsing data derived from a longitudinal BC cohort, we used bivariable and multivariable generalized estimating equation models to establish the prevalence of a benzodiazepine and opioid co-prescription and determine factors associated with this practice.

resultsBetween 1996 and 2015, 14 484 PLWH were included in the study and were followed for the entire study period. At baseline, 548 people (4%) were co-prescribed opioids and benzodiazepines, 6593 (46%) were prescribed opioids only, 2887 (20%) were prescribed benzodiazepines only, and 4456 (31%) were prescribed neither medication. A total of 3835 (27%) participants were prescribed both medications at least once during the study period. Factors positively associated with concurrent opioid and benzodiazepine prescribing included: depression/mood disorder [adjusted odds ratio (AOR) = 1.32; 95% confidence interval (CI) = 1.22-1.43] and anxiety disorder (AOR = 1.45; 95% CI = 1.27-1.66), whereas female sex (AOR = 0.76; 95% CI = 0.64-0.91) and substance use disorder (SUD) (AOR = 0.82; 95% CI = 0.74-0.90) were negatively associated with the outcome.

conclusionOur findings indicate that co-prescription of opioids and benzodiazepines was seen at some point during study follow-up in over a quarter of PLWH. Given the known risks associated with this prescribing practice, future research can focus on the outcomes of co-prescribing among this patient population and the development of strategies to reduce the co-prescribing of opioids and benzodiazepines.

Indexed as

AdultAnalgesics, OpioidAnxiety DisordersBenzodiazepinesBritish ColumbiaCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHIV InfectionsHumansMaleMiddle AgedMood DisordersPractice Patterns, Physicians'Sex FactorsAnalgesics, OpioidBenzodiazepinesBenzodiazepinesCanadaCo-prescriptionOpioidsPeople living with HIVPolypharmacy

Identifiers

PMID30897373
PMCPMC7062402
OpenAlexW2923500264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.